Q1 FY27 results analysis · August 07, 2026
Poly Medicure Ltd (POLYMED) Q1 FY27 Results Analysis: PAT Falls 8.4%, Employee Expenses Surge 70.6%
−8.4%PAT year on year, Rs. 85.27 Cr
Quick summary
Poly Medicure Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 525.38 Cr (+30.30% YoY) and PAT growth of -8.40% YoY. Here's a quick read of what worked, what to watch, and what management said.
Quick Details
| Results date | August 07, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 525.38 Cr (+30.30% YoY) |
| PAT (Q1) | Rs. 85.27 Cr (-8.40% YoY) |
| EBITDA margin | 24.11% |
| EPS (Q1) | Rs. 8.49 (-7.62% YoY) |
| Market cap | Rs. 17,172.79 Cr |
| CMP | Rs. 1,693.80 |
Quarter Snapshot
Standalone margins improved and met guidance, but consolidated PAT declined 8.4% due to acquisition cost layers and a 70.6% surge in employee expenses. The credit outlook upgrade to Positive is a positive signal, but acquisition integration and cost control remain key watch items.
Key Investment Insights
Key Positives
- Standalone EBITDA margin improved 154 bps YoY to 28.03%, at the upper end of the 25-27% guidance band
- Consolidated revenue grew 30.3% YoY to Rs.525.38 Cr
- Consolidated EBITDA margin recovered 3.1 ppt QoQ to 24.11%, within the 23-25% guidance band
- CRISIL rating outlook revised to Positive from Stable
Risk Factors
- Consolidated PAT declined 8.4% YoY to Rs.85.27 Cr despite 30% revenue growth
- Employee benefits expense surged 70.6% YoY on a consolidated basis
- Subsidiary EBITDA margin of ~6.2% is well below the group average, causing margin dilution
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Companies on this page
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.